TGTX
TG Therapeutics, Inc. $54.29 +1.25% 2026-10-02 종가 기준핵심 지표
yfinance 기준분기 실적
매출·순이익 · yfinance연간 실적 5년
SEC 10-K · 회계연도 · 달러잉여현금흐름 $-0.0B
잉여현금흐름 $-0.0B
잉여현금흐름 $-0.0B
잉여현금흐름 $-0.2B
잉여현금흐름 $-0.3B
EPS 서프라이즈
최근 4분기 · 실제 vs 예상수익성·성장
최근 12개월 기준사업 개요
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.